11/06/2018. We supported the proposal to widen access and change the funded enzyme replacement therapy for Gaucher disease.
23/4/2018. We supported the proposal to remove the funding restrictions for candesartan.
20/4/2018. We supported the proposal to list mercaptopurine oral suspension.
16/4/2018. We supported the proposal to fund aflibercept and to open list rivaroxaban tablets.
26/3/2018. We supported the proposal to widen access by removal of restrictions for endorsement and Special Authority and change the funded brand of tenofovir disoproxil and entecavir. We requested pharmacy and GP software support and educational material for pharmacists, prescribers and patients to enable a smooth transition for these medicines.
6/03/2018. We opposed the Sustagen Hospital Formula list price increase and change to part charge. We raised our concerns about the financial impact supplying special foods has on community pharmacy. We also requested resources to help explain PHARMAC price changes and for processes on dealing with PHARMAC related consumer complaints.
27/02/2018. We supported the proposal to open list montelukast tablets, removing all restrictions on the funding criteria to give patients ready access to another form of treatment for asthma and allergy.
4/11/2017. We supported the proposal to widen funded access to emtricitabine with tenofovir disoproxil fumarate (Truvada) for HIV PrEP. We asked for the OP or wastage rule to me applied to this medicine.
28/11/2017. We supported the proposal to remove the MELD score requirement for ledipasvir with sofosbuvir, as this would increase access. We raised our concerns with the XPharm supply model. We supported the proposal to widen access to tenofovir disoproxil fumarate to include women of child bearing age with active hepatitis B. We asked for the OP or wastage rule to me applied to this medicine. We supported the proposal to widen the funding criteria for paromomycin to allow treatment of E. histolyica carriage.
20/11/2017. We supported Infatrini being available to those who need it through their community pharmacy. We raised our concerns about the financial impact supplying special foods has on community pharmacy.
20/11/2017. We supported the proposal to list methylnaltrexone bromide injections for opioid induced constipation in palliative care patients. We were pleased that both a single pack and pack of seven injections will be available.
9/11/2017. We supported the proposal to widen access to zoledronic acid for early breast cancer. We did not see any concerns for community pharmacy in this proposal.
9/11/2017. We supported the proposal to fund pregabalin and change the funded brand of gabapentin and listing restrictions. We would like to understand how the funding restriction preventing concurrent use of gabapentin and pregabalin will be administered and monitored. We are pleased pharmacies will be able to claim a brand switch fee for dispensings of Apo-Gabapentin from 1 November 2018.
03/10/2017. We supported the funding of zoster vaccine to people aged 65. We voiced our disappointment that pharmacists will not initially be able to supply funded zoster vaccine to their patients, and advocated on your behalf for PHARMAC to reconsider this decision.
03/10/2017. We supported the proposal to have funded dexamethasone 700 mcg ocular implants available through community pharmacy for patients who meet the funding criteria of diabetic macular oedema.
30/08/2017. Our submission covered pack size preference, that preference should be given to a company who can supply a pharmaceutical across the different strengths, the issues very plain and generic packaging can cause, required shelf-life of pharmaceuticals, out of stock arrangements and recalls. We also opposed the proposed provision to amend the terms and conditions relating to price changes.
28/8/2017. We supported the decision to widen access to funded ciprofloxacin 0.3% eye drops for the second line treatment of chronic suppurative otitis media (CSOM), however we expressed our concern that they want to introduce subsidy by endorsement for this product.
25/8/2017. This consultation was to expand the range of CareSens self-monitoring diagnostic meters and associated test strips in the community to include a meter that tests both blood glucose and ketones (CareSens Dual) and to widen the access to diagnostic testing for all people who may need ketone testing. While we were supportive of the proposal, we requested that PHARMAC consider a reimbursement fee for community pharmacy that adequately reflects the additional work required in managing the changeover of meters.
11/8/2017. We strongly supported the proposal to allow pharmacists to provide funded NRT and ECP without a prescription. We see this as a step in the right direction for providing nationally consistent pharmacy-based services. We believe this proposal will enable the CPSA pharmacy based smoking cessation services.
11/8/2017. We supported increasing access to aripiprazole. We raised concerns about sole supply arrangements and the work required by pharmacists to switch patients from one brand to another. If the proposal goes ahead we requested pharmacies are paid a brand switch fee.
3/8/2017. We supported to continue to fund the Habitrol brand of nicotine gum, lozenges and patches supplied by GlaxoSmithKline Consumer Healthcare Limited (GSK). We raised a concern about the new 1-week packs being listed in the Schedule if supply is not through community pharmacy.
21/6/2017. While we supported the proposal for iron infusions to be fully funded when dispensed from a community pharmacy for patients with a prescription and a valid Special Authority. We pointed out community-based infusion services are not nationally consistent and would require general practices or other primary health providers to be appropriately trained, as well as to have a minimum standard of safety equipment, including resuscitation equipment. There also needs to be collaboration between the prescriber and community pharmacy to inform patients about the availability of local community-based infusion services and any related-service charges.
26/6/2017. In this submission we supported the decision to allow patient switching between erlotinib and gefitinib and the decision to list the 15mg strength of lenalidomide. We requested the wastage rule to be applied to erlotinib, gefitinib and thalidomide, and that the 5mg strength of lenalidomide was also listed. We felt we could not support the change in claiming category for thalidomide from PCT only to Retail pharmacy unless community pharmacies are reimbursed a higher handlining fee for dispensing thalidomide.
26/5/2017. In this submission included we supported changes in the funding criteria for antiretrovirals, azithromycin, lamivudine, ledipasvir and sofosbuvir, and roxithromycin, as this would improve access to these medicines. We requested the OP or wastage rule was applied to antiretrovirals and lamivudine. We asked for the supply model of ledipasvir and sofosbuvir to be revised, and we thought the funding of roxithromycin dispersible tablets should be extended to include adults and children over 12 years of age who are unable to swallow tablets.
As a result of this submission PHARMAC decided to add the OP rule to lamivudine oral liquid 5 mg per ml.
26/5/2017. We supported the decision to fund modified-released melatonin for insomnia in children and adolescents with neurodevelopmental disorders subject to Special Authority conditions. We also suggested the funding was extended to include treatment of insomnia in people aged 55 and over.
16/5/2017. While we supported the proposal to change the way in which funded condoms and nicotine replacement therapy (NRT) pharmaceuticals are delivered in bulk to certain organisations, we did not feel the proposal would meet PHARMACs goals of widening options for providing funded pharmaceuticals to patients, removing barriers to access and ensuring that the pharmaceutical funding system remains fit-for purpose and sustainable. We proposed an alternative supply model through community pharmacy which would allow request of supplies by these organisations on an as needed basis.
12/5/2017. We supported midazolam injections being made available on PSO for use in status epilepticus. We however requested the quantity to be changed to reflect an original pack size. We also supported enoxaparin access being widened to include during home haemodialysis. We asked for the OP or wastage rule to be applied to all dispensings of enoxaparin.
As a result of this submission PHARMAC changed the quantity of midazolam available on a PSO equal to that of an original pack.
10/04/2017. While we had no reasons to object the decision to list AstraZeneca’s Betaloc CR brand of metoprolol succinate long-acting tablets, we raised our concerns about sole supply arrangements and continuity of supply.
22/02/2017. We strongly support the proposed changes to the Pharmaceutical Schedule to fund the provision of influenza vaccine (flu vaccine) in community pharmacies to people 65 years and over and pregnant women. These changes will make use of the additional skills of vaccinating pharmacists, and support an integrative care model.
13/12/2016. Our submission covered pack size preference, that preference should be given to a company who can supply a pharmaceutical across the different strengths, the issues very plain and generic packaging can cause, required shelf-life of pharmaceuticals, out of stock arrangements and recalls.
6/12/2016. We believe that community pharmacies should become Authorised Providers to provide increased access to NRT service for patients attempting to quit smoking, including the benefit of the ‘walk-in’ no appointment service that community pharmacies offer.
28/10/2016. We supported the addition of pirfenidone capsules to the Pharmaceutical Schedule for the treatment of idiopathic pulmonary fibrosis. We ask that PHARMAC lists the 63 capsule pack of pirfenidone to prevent wastage of this medicine. If it is not possible to list this alternative pack size then please apply the wastage or original pack rule to pirfenidone to reduce this significant financial risk to community pharmacies when they dispense this potentially life changing medicine.
We supported the addition of Harvoni and Viekira Pak, as these treatments would provide funded access to major advances in Hepatitis C treatment for New Zealanders infected with the disease. We raised concern about these products being listed in Section B of the Schedule as XPharm items, as this means pharmacies would not be able to claim subsidy as alternative distribution arrangements would be put in place by PHARMAC. PHARMAC received a lot of feedback regarding the proposed direct distribution mechanism for the hepatitis C treatments from the pharmacy sector. We have been advised that this feedback will result in some changes being made to the originally proposed distribution mechanism.
We supported the decision to widen the access for longer term azithromycin treatment to include the prevention of exacerbations of non-cystic bronchiectasis for children, and mycobacterium avium intracellular complex infections, and agreed that for short courses of azithromycin should be limited for specific indications only. We however raised concerns regarding the administration of the subsidy by endorsement for short courses, as in the past subsidy by endorsement has proven to be problematic, as the endorsement is often absent from the prescription. Our view was that the prescribing of short courses of azithromycin should remain a responsibility of best practice through prescribing guidelines rather than requiring an endorsement by the prescriber.
We supported the intention of the proposal to widen access for particular patient groups to certain Special Foods however, this proposal provides another example of community pharmacies carrying the burden of some Schedule changes. We reminded Pharmac that community pharmacies are losing money when dispensing Special Foods and cannot sustain the ongoing loss through the provision of special foods to their patients. We requested an acknowledgement in the schedule that special foods are not fully reimbursed into pharmacy and a mechanism, like the product premium, to formalise the current situation whereby pharmacists pass on funding shortfalls on special foods to their patients.
We responded to Pharmac’s proposal for allowing community funded medicines (initially vaccines) and devices to be distributed directly to primary care providers. We believe that patients already have excellent access to medicines in General Practice through the existing mechanisms and wanted to understand how the approach outlined would improve patient access and safety. The Guild’s view is that it is vital that a distinct separation exists between prescribing and dispensing of a medicine. Community pharmacy is an important gatekeeper of medication safety. Changing the system so that some of that supply came from GPs would be hugely inefficient, as this would involve distribution of smaller orders to many more sites with no expectation of improvement in patient safety or adherence and in fact potentially the opposite.
We supported the listing of a registered brand of sodium phenylbutyrate granules that will provide a treatment for patients with rare urea cycle disorders, as currently it is available in New Zealand as a section 29 medicine only. We were pleased to see that this medicine would be listed only after Medsafe grants its registration. We requested that this medicine is funded as an original pack (OP) or the wastage rule applied as it is a very high cost medicine. As it is packaged as a bottle of loose granules, we would expect that there would be no other option for dispensing other than as an OP.
We drew PHARMAC’s attention to the issue of price support for when proposals are likely to result in a significant price drop for a medicine. In the case of this proposal, the price drop for these medicines had the potential to impact both pharmacies and patients. We requested that PHARMAC insist that manufacturers provide ‘price support’. This would ensure that patients have ready access to the medicines they need and that wholesalers and pharmacies will not be financially disadvantaged when they keep stock on hand in advance of the prescription being presented.
We requested that PHARMAC consider the labelling of medicines as part of their tender process and only select or purchase those products that will result in clarity in the pharmacy and for the patient. We believe that providing more detailed labelling preferences to suppliers will result in reduced harm from medication errors and help to improve patient safety.
We supported the widening of access for the diphtheria, tetanus and pertussis (Tdap) vaccine. We requested for pharmacists to be funded as well as other primary care providers to provide this vaccine. PHARMAC stated they were working closely with the Ministry of Health and the DHBs to consider this.
We requested that the wastage rule be applied for a new listing for glycopyrronium bromide for terminally-ill patients and also requested PHARMAC review the original pack status for several high cost medicines having amendments made to their Schedule restrictions. While PHARMAC did not apply the wastage rule in this instance, they stated they would reconsider this decision should information be provided to show that significant wastage was occurring.
We supported the proposal to list Nitrolingual Pump Spray. We had received significant feedback from members concerned about patients unable to effectively use the Glytrin brand.
We requested pack size alignment with the Schedule e.g. a 90-day supply for stat medicines. We asked PHARMAC to consider the impact of formulation and wastage in their decisions, and also the safety implications of generic packaging. We requested a funding mechanism to compensate community pharmacy for out-of-stock situations.
We were supportive of the funding of two new treatments for this disease. We were concerned at the potential for community pharmacy to be left with part-packs of one of the medicines and requested the wastage rule or original pack dispensing be applied to this. PHARMAC applied the wastage rule to this medicine.
We supported the wide range of treatments that would be made accessible to patients. Many of these medicines were very high cost (up to $6532 per pack) and we were concerned at the potential financial risk this posed to community pharmacy. We requested the wastage rule be applied to five of these medicines, and we were successful with this request.
We supported the removal of Special Authority restrictions for the six medicines listed in the proposal (e.g. bicalutamide, mycophenolate) as it would result in greater efficiencies for all involved – prescribers, PHARMAC, pharmacists and patients. We also supported the widening of funded access to eight medicines including isotretinoin and acitretin.
Pharmac has released its tender document for 2014/15, inviting tenders for the supply of certain pharmaceuticals to DHB hospitals and community pharmacies.
We had concerns regarding the potential for wastage of lenalidomide and thalidomide, as these are very high cost medicines. We requested that either the wastage rule or original pack dispensing be applied to these listings. PHARMAC applied the wastage rule to lenalidomide.
We were supportive of the increased availability to patients for this medicine. We had concerns regarding generic prescribing and asked PHARMAC why the two forms of erythropoietin (alfa and beta) were not considered generically equivalent. We asked for Special Authority approval to coincide with normal prescribing practice of three months. PHARMAC applied the wastage rule to this medicine.
We agreed that the proposal would be of benefit to patients as it would give them access to an increased range of subsidised NSAIDs. We had concerns about the endorsement requirement for diclofenac 50mg dispersible tablets and the potential burden that it placed on community pharmacy when prescriptions are incomplete. We requested PHARMAC make prescribers aware of the endorsement requirement to ensure that patients received a fully funded medicine.